

US009353050B2

(12) United States Patent Kovi et al.

(10) Patent No.: US 9,353,050 B2 (45) Date of Patent: May 31, 2016

(54) PROCESS FOR PREPARATION OF ISOSULFAN BLUE

(75) Inventors: Ravishanker Kovi, Monroe, NJ (US);

Satyam Nampalli, Belle Mead, NJ (US); Peter Xavier Tharial, Piscataway, NJ

(US)

(73) Assignee: Apicore US LLC, Somerset, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 584 days.

(21) Appl. No.: 13/310,019

(22) Filed: **Dec. 2, 2011**

(65) **Prior Publication Data**

US 2012/0078007 A1 Mar. 29, 2012

Related U.S. Application Data

- (63) Continuation of application No. 12/643,056, filed on Dec. 21, 2009, now abandoned, which is a continuation of application No. 12/180,057, filed on Jul. 25, 2008, now Pat. No. 7,662,992, which is a continuation of application No. 11/747,291, filed on May 11, 2007, now abandoned.
- (51) **Int. Cl.** *C07C 303/02* (2006.01) *C07C 303/22* (2006.01)
- (58) **Field of Classification Search**CPC C09B 11/10; C07C 309/22; C07C 309/52
 USPC 564/80; 562/58, 59
 See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

3/1925	Rosenbaum
5/1931	Schmidt
9/1932	Kyrides
6/1947	Stryker
12/1955	Balon
5/1982	Hermann
	5/1931 9/1932 6/1947 12/1955

4,710,322 A 12/1987 Metz 5,659,053 A 8/1997 Gessner et al. 2006/0224003 A1 10/2006 Kulkarni

OTHER PUBLICATIONS

Dan et al., "1% Lymphazurin vs. 10% Fluorescein for Sentinel Node Mapping in Colorectal Tumors," Arch. Surg., 139, 1180-1184, 2004.*

Argentine et al., "Strategies for the investigation and control of process-related impurities in drug substances," Advanced Drug Delivery Reviews, 59, 12-28, 2007.*

Hiranaka et al., "Chemical Structure and Purity of Dyes Used in Lymphangiograms," Investigative Radiology, 10(1), 79, 1975.*

Rodd's Chemistry of Carbon Compounds by S. Coffey, 1974 2nd Edition vol. III Part F 110-113.

International Search and Written Opinion of Apr. 23, 2003 of International Application No. PCT/US07/84051.

Office Action for corresponding U.S. Appl. No. 12/180,057, dated Feb. 23, 2009.

Office Action for corresponding U.S. Appl. No. 11/747,291, dated Feb. 7, 2008.

Office Action for corresponding U.S. Appl. No. 12/643,056, dated Jul. 19, 2011.

Coleman et al., "Unexplained Decrease in Measured Oxygen Saturation by Pulse Oximetry Following Injection of Lymphazurin 1% (isosulfan Blue) During a Lymphatic Mapping Procedure", Journal of Surgical Oncology 1999, 70: 126-129.

* cited by examiner

Primary Examiner — Paul A Zucker
Assistant Examiner — Mark Luderer
(74) Attorney, Agent, or Firm — Timothy X. Gibson; Gibson & Dernier LLP

(57) ABSTRACT

A process for the preparation of isosulfan blue (Active Pharmaceutical Ingredient) is provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon mild oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.

18 Claims, No Drawings